How does immunoembolization compare to the FOCUS trial for uveal melanoma?
For patients with liver-dominant metastatic uveal melanoma, immunoembolization is an established treatment option. However, a direct comparison with the FOCUS trial, which uses melphalan via percutaneous hepatic perfusion, indicates that immunoembolization results in lower disease control rates 35. While immunoembolization has its place, other systemic therapies like tebentafusp combined with local radiotherapy have shown promise in maintaining disease control for specific patient groups 2.
What the research says
A single-center retrospective analysis compared immunoembolization outcomes against the Phase 3 FOCUS trial data. The study found that the overall disease control rate for immunoembolization was lower than what was reported in the FOCUS trial 35. The FOCUS trial evaluated melphalan delivery directly into the liver, a method that demonstrated superior efficacy in controlling the disease compared to the immunoembolization procedures reviewed in this analysis 35.
What to ask your doctor
- What are the disease control rates for immunoembolization versus the FOCUS trial approach for my specific case?
- How does my HLA genotype affect whether I am a candidate for tebentafusp combined with radiotherapy?
- What are the potential benefits and risks of combining liver-directed therapy with immune checkpoint inhibitors?
- Is there a clinical trial available that compares different liver-directed therapies for metastatic uveal melanoma?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.